We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EAP

News List

NRx Pharmaceuticals’ Zyesami yields positive data in EAP for Covid-19 pharmaceutical-technology
June 17, 2021
NRx Pharmaceuticals has reported positive results from the expanded access protocol (EAP) of its Zyesami (Aviptadil) in critical Covid-19 patients admitted to the ICU with respiratory failure.
BrainStorm Announces NurOwn Expanded Access Program americanpharmaceuticalreview
January 05, 2021
BrainStorm Cell Therapeutics has announced the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the Company's recently concluded pivotal Phase 3 clinical trial ...
Expanded access for compassionate use of remestemcel-L in COVID-19 infected children europeanpharmaceuticalreview
July 08, 2020
US expands access to remestemcel-L for compassionate use in COVID-19 infected children with complications of multisystem inflammatory syndrome.